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Abstract
Background: The androgen receptor (AR) plays important roles in the development of male phenotype and in different
human diseases including prostate cancers. The AR can act either as a promoter or a tumor suppressor depending on cell
types. The AR proliferative response program has been well studied, but its prohibitive response program has not yet been
thoroughly studied.
Methodology/Principal Findings: Previous studies found that PC3 cells expressing the wild-type AR inhibit growth and
suppress invasion. We applied expression profiling to identify the response program of PC3 cells expressing the AR (PC3-AR)
under different growth conditions (i.e. with or without androgens and at different concentration of androgens) and then
applied the newly developed ChIP-seq technology to identify the AR binding regions in the PC3 cancer genome. A
surprising finding was that the comparison of MOCK-transfected PC3 cells with AR-transfected cells identified 3,452
differentially expressed genes (two fold cutoff) even without the addition of androgens (i.e. in ethanol control), suggesting
that a ligand independent activation or extremely low-level androgen activation of the AR. ChIP-Seq analysis revealed 6,629
AR binding regions in the cancer genome of PC3 cells with an FDR (false discovery rate) cut off of 0.05. About 22.4% (638 of
2,849) can be mapped to within 2 kb of the transcription start site (TSS). Three novel AR binding motifs were identified in
the AR binding regions of PC3-AR cells, and two of them share a core consensus sequence CGAGCTCTTC, which together
mapped to 27.3% of AR binding regions (1,808/6,629). In contrast, only about 2.9% (190/6,629) of AR binding sites contains
the canonical AR matrix M00481, M00447 and M00962 (from the Transfac database), which is derived mostly from AR
proliferative responsive genes in androgen dependent cells. In addition, we identified four top ranking co-occupancy
transcription factors in the AR binding regions, which include TEF1 (Transcriptional enhancer factor), GATA (GATA
transcription factors), OCT (octamer transcription factors) and PU1 (PU.1 transcription factor).
Conclusions/Significance: Our data provide a valuable data set in understanding the molecular basis for growth inhibition
response program of the AR in prostate cancer cells, which can be exploited for developing novel prostate cancer
therapeutic strategies.
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Introduction
Androgens and the androgen receptor (AR) play important
biological roles in the development of male phenotype and
urogenital tissues, including prostate, and in the initiation and
progression of many human diseases. Alterations in AR sequences
and expression levels and perturbations in AR signaling networks
have significant roles in the genesis and maintenance of prostate
cancers (PCa) [1–6]. Prostate cancers are often treated with
hormone deprivation strategies such as orchidectomy, a luteinizing
hormone-releasing hormone (LHRH) analogue, or an antiandro-
gen. Although they are initially responsive to the treatment
strategy, nearly all prostate cancers progress to ‘hormone-
refractory’ or ‘androgen-independent’ disease. There are data
suggesting that the AR signaling is still functional in ‘hormone-
refractory’ prostate cancer (HRPC). The mechanisms include 1)
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6589activation of the AR by other growth factors [7]; 2) mutations in
the AR that change AR ligand specificity and allow AR to be
activated by non-steroids or anti-androgens [8]; 3) over-expression
of the AR [2,9–11]; 4) recruitment of new AR-cofactors [12].
These data suggest that the AR seems to act as a promoter of
carcinogenesis in HRPC.
In contrast, Yuan et al. showed an androgen-induced inhibition
of cell proliferation in an androgen-insensitive prostate cancer cell
line (PC3) transfected with a human androgen receptor comple-
mentary DNA. They showed that in PC3 cells expressing the
transfected androgen receptor (PC3-AR) under the simian virus 40
(SV40) promoter, androgen decreased the proliferation rate and
cloning efficiency and induced a more differentiated phenotype.
Their data demonstrated that PC3 cells have retained the cellular
machinery required to respond to the activated androgen receptor.
Similar results were obtained showing that androgens suppress the
proliferation of PC3-AR cells using two other promoters:
cytomegalovirus (CMV) promoter [13] and the EF1a promoter
[14].
Niu et al. recently found that AR is a tumor suppressor or a
proliferator in prostate cancer depending on cellular contexts
[15,16]. Niu et al. studied the effects of AR in the PC3-AR9 cells,
which are PC3 cells expressing the AR under the control of its own
native promoter [17]. They found that restoring the AR in PC3
cells could suppress their in vitro and in vivo invasion capabilities. All
these data generated in PC3 cells seem to contradict the traditional
belief that the AR functions as a stimulator in prostate tumor
growth and metastasis. As PC3 cells expressed the basal marker-
CK5 [18], PC3 cells might have some basal cell properties, which
make them different from other prostate cancer cell lines such as
LNCaP, which expresses CK8/18 and shows luminal cell
properties [18].
We hypothesize that PC3 cells possess cellular machinery that
turn the AR in PC3-AR cells into growth suppressor. We applied
expression profiling to identify the response program of PC3-AR
cells to different growth conditions (i.e. with or without androgens
and different concentration of androgens) and then applied the
newly developed ChIP-seq technology to identify the AR binding
regions under androgen deprivation conditions. Out data provide
a valuable data set in understanding the molecular basis for the
growth prohibitive response program of the AR in advanced
prostate cancers. The growth prohibitive properties of the AR or
its response program can be exploited for developing novel
prostate cancer therapeutic strategies.
Results
PC3 cells expressing AR initiate ligand independent
activation of the AR response program
In an effort to characterize androgen-induced growth inhibition
mechanism and to identify targets that could be used to induce
growth inhibition and differentiation in advanced prostate cancer
cells, we used PC3 cells transfected with the wild-type AR as a
model and performed gene expression profiling analysis. We
compared PC3 cells with or without harboring the wild-AR
construct in the growth conditions of 1 nM R1881, 10 nM R1881
and ethanol (the solvent for R1881). The MOCK control is PC3
cells transfected with empty vectors.
To our surprise, the comparison of MOCK-transfected PC3
cells with AR-transfected cells showed 3,452 genes with differential
expression (two fold cutoff) even without addition of androgens (i.e.
in ethanol control) (Table S1 and Figure 1). A carefully repeated
biological replicate showed consistent results. This suggests that
other factors than androgens could initiate AR-mediate response
without the canonical AR binding ligand androgens. Alternatively,
as we used charcoal-stripped serum, which still has about 10% of
androgens remaining in the serum [7], it may suggest that low
levels of androgen can still activate a large number of genes
through AR in the advanced prostate cancer cell PC3. Among
these 3,452 genes, 2235 are down regulated genes and 1217 up
regulated genes in AR-PC3 cells compared to MOCK-transfected
cells (Table S1). Adding 1 nM androgen only adds 232
differentially expressed genes (two fold cutoff, 133 down regulated
and 101 up regulated). Adding 10 nM R1881 (androgens)
generated an additional 482 differentially expressed genes (324
down regulated and 159 up regulated) (Figure 1). The union of all
three comparisons generated a total list of 4,166 genes that can be
regulated by androgens in various concentrations (Table S1). The
array data were submitted to Gene Expression Omnibus (GEO)
with accession number GSE15091 (http://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE15091).
Functional characterization of the differentially expressed
genes between PC3-AR cells and Mock-transfected cells
Using GOminer analysis [19], we found that, in the up-
regulated genes in PC3-AR cells compared to Mock-transfected
cells, the most significantly enriched GO term is negative
regulation of biological process (GO:0048519), suggesting a
general down-regulation of biological process in AR-PC3 cells,
which is consistent with the observation that over-expression of
AR in PC3 cells inhibits cell proliferation [20]. Other interesting
enriched GO terms include GO:0008283 cell proliferation,
GO:0012501 programmed cell death, GO:0007249 I-kappaB
kinase NF-kappaB cascade, GO:0007259 JAK-STAT cascade,
GO:0042509 regulation of tyrosine phosphorylation of STAT
protein (Table 1 and table S2).
The GO terms enriched by the down regulated genes include
GO terms involved in transport and cellular localizations, and in
general metabolic process such as the TCA (GO:0006099
tricarboxylic acid cycle) cycle, which again is consistent with the
growth inhibition phenotype observed (Table 2 and table S2).
Identification of global ligand-independent AR binding
sites by ChIP-seq analysis in PC3-AR cells
In order to identify the direct targeted genes of AR in the
ligand-independent AR response program, we performed ChIP-
seq of the DNAs from anti-AR chromatin IP, as described by
Barski et al. [21]. Through commercialization of the second
generation of high throughput technologies (e.g. from Illumina-
Solexa, Roche and ABI/SOLiD), ChIP-seq technology is rapidly
emerging as a cost effective, global technology for high-resolution,
genome-wide, unbiased mapping of protein-DNA interactions in
chromatin-mapped complexes. It has been applied in global
identification of in vivo binding of the insulator binding protein,
CTCF [21], the neuron-restrictive silencer factor (NRSF) and
STAT1 [22,23]. Ji et al. recently showed that ChIP-seq has better
ability than ChIP-Chip in identifying TF binding regions for
NRSF [24]. Therefore, we adopted the ChIP-seq approach in this
study.
The same transfected PC3 cells as we used for gene expression
profiling were used for ChIP-seq analysis. Transfected PC3 cells
were grown without the addition of androgens. After ChIP-seq
analysis, we obtained a total of 5,354,469 20-nucleotide (nt)
sequence tags that can be mapped uniquely to the human genome
allowing up to two mismatches to accommodate normal
polymorphisms. We also performed ChIP-seq analysis for IgG
negative controls and obtained 1,089,089 tags.
The AR Program in PC3-AR Cells
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the promoter region of the gene BACH1 on chromosome 21. We
used the CisGenome program [24] to systematically identify DNA
binding regions of AR. Analysis using the EXPLORE algorithm of
the CisGenome showed a strong enrichment for AR ChIP reads
(with the dP0 hat at 0.7526). Using an FDR (false discovery rate)
cut off of 0.05, we identified a total of 6,629 AR binding regions in
the PC3 cells (Table S3). Among them, 4435 AR binding regions
(about 67%) can be mapped to 3592 genes with unique Refseq IDs
using the closest distances of 50 kb to the TSS start or end sites as
criteria, suggesting that a gene can contain multiple AR binding
regions. Using Entrez IDs as identifiers, 4435 AR binding regions
Table 1. Enriched GO terms in up regulated list in PC3-AR cells compared to MOCK-transfected cells.
GO CATEGORY Total Genes Changed Genes Enrichmentt LOG10(p)
GO:0008283_cell_proliferation 507 58 1.47 22.86
GO:0012501_programmed_cell_death 425 67 2.03 28.15
GO:0006915_apoptosis 423 67 2.04 28.24
GO:0007249_I-kappaB_kinase_NF-kappaB_cascade 104 20 2.48 23.94
GO:0045595_regulation_of_cell_differentiation 64 12 2.41 22.48
GO:0007259_JAK-STAT_cascade 31 8 3.32 22.70
GO:0042509_regulation_of_tyrosine_phosphorylation_of_STAT_protein 10 4 5.15 22.29
GO:0042771_DNA_damage_response__signal_transduction_by_p53_class_
mediator_resulting_in_induction_of_apoptosis
5 3 7.73 22.38
doi:10.1371/journal.pone.0006589.t001
Figure 1. Venn diagrams showing the number of genes regulated in the three comparisons (ETOH vs. Mock, 1 nM vs. Mock, 10 nM
vs. Mock) (the Top Panel), and the number of up or down regulated genes in each comparison (the Bottom Panel). We noted that two
genes (S100A4 and MME) are up regulated in the condition of 1 nM R1881 but down regulated in the ethanol condition comparing to the MOCK
control, and one gene HSPD1 is up-regulated in the condition of 10 nM R1881 but down regulated in ethanol. It causes the disagreement of number
of genes between Venn-diagrams in the top panel and that of the lower panel.
doi:10.1371/journal.pone.0006589.g001
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IDs. The average number of AR binding regions per gene is 1.26.
The rest of them (2,194 AR binding regions, about 33%) could be
mapped to more than 50 kb away from the transcript starts or
ends of known genes or to regions that have not yet been
annotated to be associated with genes in the human genome.
The top 10 mostly strong AR binding regions by the number of
sequence tags mapped contain the genes for ATIC (IMP
cyclohydrolase), TUSC1 (Tumor suppressor candidate 1), AQP2
(Aquaporin 2), GFRA1 (GDNF family receptor alpha 1), PACRG
(PARK2 co-regulated), OR1J1 (Olfactory receptor, family 1,
subfamily J, member 1) and genes with unknown functions such as
KIAA0350 and FAM118A (Family with sequence similarity 118,
member A). Interestingly, among the top ten AR binding regions,
there are two AR binding regions (chr2: 19587584–19587634 and
chr16: 74498964–74498992) that seem not mapped to any known
genes. However, chr16: 74498964–74498992 is about 46 kb away
form spliced EST BX094831, and chr2: 19587584–19587634 is
about 35 kb from spliced EST BG219799, suggesting that these
two genes may be the genes yet to be fully characterized and
possibly regulated by the AR.
To confirm that ChIP-seq is able to identify AR binding in
genes, we randomly picked 5 genes and confirmed enrichment of 4
genes in the ChIP DNA pulled down by the AR antibody
compared to ChIP DNA pulled down by the mouse IgG control
(Table 3). The FDR rate calculated by this strategy is 20%.
Categorization of the AR binding regions identified by
ChIP-seq based on their relative positions to genes
We then mapped these binding regions to the human genome
and categorized these binding regions based on their locations
relative to the genes in the human genome using the CisGenome’s
annotation functions. The mapping was done with the gene
annotations from the UCSC genome annotation database (09/05/
2008) for the human genome (hg18, Build 36.1). We tabulated the
frequencies of AR binding sites to the transcription start sites
(TSSs) for every two kilo bases. A histogram of AR binding sites
residing within the downstream 50 kb or upstream 50 kb genomic
regions relative to annotated TSSs is shown in Figure 3. Most of
the AR binding regions was identified around the TSS sites
(Figure 3). About 22.4% (638 of 2,849) can be mapped to within
2 kb of the transcription start site (TSS).
Correlation of AR binding with gene expression data
To answer the question whether ligand-independent AR
binding to the genomic regions exerts functional consequences
through changes in the expression level of the targeted genes, we
integrated the ChIP-seq data with gene expression profiling data.
2163 AR binding genes (2679 AR binding regions) identified by
ChIP-seq have corresponding genes on the array we used for
expression profiling analysis. Comparing the expression profiling
data with the ChIP-seq data, we identified a total of 727 genes
(937 AR binding regions) for which the genes were changed by
two fold in the ETOH vs. Mock comparison; among them, 543
genes (716 AR binding regions) were down regulated, and 184
genes (221AR binding regions) were up-regulated. Addition of
1 nM R1881 generated an additional 43 genes (28 down regulated
and 15 up regulated), and addition of 10 nM R1881 identified a
further 89 genes (66 down regulated and 23 up regulated). The
union of the three analyses identified a total of 859 genes (1114 AR
binding regions) (51.5%, 1,114/2,163,) that are differentially
expressed at various concentrations of androgens by at least two
fold (Table S3 and Figure 1, lower panel). Among the 859 genes
that contain AR binding sites and are changed in expression levels
in response to androgen treatments, 637 genes are down regulated
while 222 genes are up regulated. We found that the androgen
regulated genes in PC3-AR9 cells are significantly enriched for AR
binding sites (with one-sided Fisher’s exact test, P=1.82e-11).
Identification of ARE consensus in the AR binding regions
The androgen receptor regulates the transcription of specific target
genes by binding to specific DNA response elements in their
promoters, referred to as androgen response elements (AREs)
[25,26]. In the Transfac database, there are three AREs derived
from in vitro binding data or from a limited numbers of human
promoters: the M00481 (consensus: GGTACANNRTGTTCT)[25];
M00447 (consensus sequence AGWACATNWTGTTCT)[26];
M00962 (consensus sequence WGAGCANRN). To see how many
AR motifs were found in the AR binding regions, we loaded the AR
matrix (obtained from the Transfac TF database) tables for M00481,
M00447 and M00962 into the CisGenome program to compare to
all AR binding regions that we identified in PC3 cells with a
likelihood (LR) ratio of 500 compared to genomic background. We
identified 40, 21, 147 respectivelyfor M00481, M00447 and M00962
(Table S4). The union of the above three gives 190 sites (about 7.1%,
190 out of 2,679 AR binding regions). Searching against the AR
binding regions with the AR half-site motif TGTTCT with the
criterion of allowing no mismatches, we identified 226 binding
regions (about 8.4%) that contain the AR half-site motif.
Since the percentage of the ARE identified in our AR binding
regions is low, we asked the question whether there exists novel AR
binding motifs in the AR binding regions of PC3 cells. We
hypothesize that the AR binding motif in the prohibitive responsive
PC3-AR cells might be different from that in the proliferative
prostate cancer cells. We therefore used the Gibbs Motif Sampler of
the CisGenome program to identify novel AR binding motifs. With
a likelihood (LR) ratio of 500 compared to AR IGG ChIP-Seq
background, we identified five novel putative AR binding motifs.
Two of these motifs are general GC rich or AT rich sequence motifs
and may not be specific and were discarded. The reminding three
new motifs were named AR new motif Gib1 to 3. AR new motif
Table 2. Enriched GO terms in down regulated list in PC3-AR cells compared to MOCK-transfected cells.
GO CATEGORY Total Genes Changed Genes Enrichmentt LOG10(p)
GO:0046907_intracellular_transport 282 53 1.56 23.32
GO:0006892_post-Golgi_vesicle-mediated_transport 14 7 4.16 23.25
GO:0006099_tricarboxylic_acid_cycle 7 4 4.76 22.27
GO:0046356_acetyl-CoA_catabolic_process 7 4 4.76 22.27
GO:0009081_branched_chain_family_amino_acid_metabolic_process 6 5 6.94 23.87
doi:10.1371/journal.pone.0006589.t002
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respectively (Table S5, S6, S7). The union of the AR binding
regions containing one of these two motifs is 1,808 AR binding
regions, i.e. 27.3% of AR binding regions, (1,808/6,629), which is
much higher than the number of mapped AR binding regions by
the known canonical AR motif from the Transfac database. The
consensus logos of the new AR motifs are shown in Figure 4. They
have a core sequence motif CGAGCTCTTC. We were curious
Table 3. RT-PCR confirmation of AR binding regions in PC3-AR cells.
Gene Symbol Description RT-PCR Ratio AR ChIP/IgG ChIP
GSK3B Glycogen synthase kinase 3 beta 3.03
OR9Q1 Olfactory receptor, family 9, subfamily Q, member 1 25.03
TADA2L Transcriptional adaptor 2 (ADA2 homolog, yeast)-like 3.26
ZNF533 Zinc finger protein 533 3.26
ARL16 ADP-ribosylation factor-like 16 0.79
doi:10.1371/journal.pone.0006589.t003
Figure 2. An example of the mapping of the ChIP-seq tags to a region in the human chromosome 21. Each black bar represents a unique
ChIP seq taq mapped to the region. The promoter region of the BACH1 (BTB and CNC homology 1, basic leucine zipper transcription factor 1)
contains a peak of ChIP-seq tag alignments to this chromosomal region, suggesting that the AR binds to this promoter. The figure was generated by
uploading to the UCSC genome browser a file containing all unique ChIP seq tags in the BED format. Annotations are from the UCSC genome
browser.
doi:10.1371/journal.pone.0006589.g002
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motifs. Using JASPAR: an open-access database for eukaryotic
transcription factor binding profiles (http://jaspar.genereg.net/
)[27], we found that the highest ranked match is to NR3C1 with
score of 14.5926 (72.96 percentage score). NR3C1 is the nuclear
receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
gene. Interestingly, both AR and the NR3C1 belong to same SCOP
(Structural Classification of Proteins) family ‘Nuclear receptor
ligand-binding domain’ (http://scop.mrc-lmb.cam.ac.uk/scop/
data/scop.b.b.cdh.b.b.html). They are very similar in structure,
with the RMSD (root mean square deviation) between two
structures being 1.35 angstrom although the sequence similarity is
only 47%. However, a search using the NR3C1 matrix using the
CisGenome program with the same criteria we used previously only
identified 53 matches to NR3C1 motif, suggesting that the NR3C1
motif, although is the highest ranking matches of known TFs, is
different from the new motifs we identified. The new motif we
identified with the core sequence CGAGCTCTTC is truly a novel
motif not previously defined.
We were curious whether other known TFs could be bind to the
AR binding regions that we identified and act as AR cooperators
for regulation of gene expression. In order to systematically search
for potential bindings of other transcription factors, we used the
MotifScanner program (http://homes.esat.kuleuven.be/,thijs/
download.html) and scanned all TF motifs (PWM databases)
using the human transcription factor subset of the Transfac
professional 7.0. The matrices with the top ranking matches
include TF matrix TEF1_Q6 (Transcriptional enhancer factor),
GATA_Q6 (GATA transcription factors), OCT_Q6 (octamer
transcription factors) and PU1_Q6 (PU.1 transcription factor) with
frequencies of 7.8%, 6.3%, 5.2%, 5.2%, respectively. The result of
motif scanning is provided as table S8. Interestingly, the matrices
with the top 10 ranking matches contain three GATA TF
matrices: GATA_Q6, GATA1_04 and GATA3_01 (Table S8),
suggesting that GATA family matrix might be the one of the
highest co-occurrence TF in the AR binding regions of PC3-AR
cells.
Discussion
We showed that AR could be activated in low androgen or
ligand independent manner in advanced prostate cancer cell line
PC3 cells expressing the AR. the comparison of vector-transfected
PC3 cells with AR-transfected PC3 cells showed that 3,449 genes
are differentially expressed (two fold cutoff) even without addition
of androgens (Figure 1 and table S1). This observation could be
due to remaining low level of androgens in the medium, or due to
androgen-independent activation of AR, or a combination of both.
Page et al. recently showed that in patients with medical
castration, although there is a 94% decrease in serum T,
intraprostatic T and dihydrotestosterone levels remained 20–
30% of control values, and prostate cell proliferation, apoptosis,
and androgen-regulated protein expression were unaffected. The
concentration of androgens remains in our culture condition using
charcoal striped serum will probably similar to those or lower than
those obtained by medical castration as charcoal stripped serum
still has about 10% of androgens remaining in the serum [7]. Yuan
et al. found that DHT concentration as low as 0.1 nM was able to
inhibit cell proliferation of PC3 cells expressing AR by more than
40% after 72 h of incubation [20].
The PC3-AR expression model is in contrast to the androgen-
sensitive and widely used LNCaP cell line, which, although
expresses AR, but harbors a mutated AR (a missense mutation
T877A) that confers promiscuity in its ligand binding. The mutated
AR in LNCaP cells can be activated not only by androgens but also
by progesterone, estrogen, adrenal androgens, and hydroxyf
lutamide [28,29]. The PC-3 was initiated from a bone metastasis
of a grade IV prostatic adenocarcinoma from a 62-year-old male
Caucasian [30]. Several studies demonstrated that PC PC3 cells
expressing the transfected androgen receptor (PC3-AR) show
growth inhibition and reduced invasion capabilities [13–16,20].
Gene Ontology analysis of differentially expressed genes demon-
strated that the activated AR program in PC3-AR cells are mostly
involved in negative regulation of biological process, which is
consistent with the growth inhibition properties of pC3-AR cells
Figure 3. Histograms of AR binding sites around annotated TSS (Transcription start sites) (+ or 250 kb). Frequencies of AR island
binding were calculated every two kilobases (Y-axis). Relative distance to TSS is shown in X-axis, Negative and positive values indicate localization 59
or 39 to TSS respectively.
doi:10.1371/journal.pone.0006589.g003
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our PC3-AR expression model with two AR GEGs published
previously by Deprimo et al. [31] and Nelson et al. [32] from
LNCaP cells revealed that the overlap is not significant (one-sided
Fisher’s exact test P=0.9996, and the p-value from Gaussian fitting
of 10,000 random sampling is 1), again suggesting that the AR
response programs in these two model systems are different. We
hypothesize that the different sets of AR co-regulators between
LNCAP and PC3-AR cells can explain the difference in the AR
response programs between the PC3-AR and the LNCaP models.
Cell-line and tissue-specific androgen receptor-coregulators have
been documented by Bebermeier et al. [33].
We applied ChIP-seq technology to build a genome-wide high-
resolution map of the AR binding regions in PC-3 cell line
transfected with the AR. About 22.4% (638 of 2849) of the AR
binding regions in PC3-AR cells can be mapped to within 2 kb of
the transcription start site (TSS) (Figure 2) and about 62.2% (2,849
of 4,435) of the AR binding regions could be mapped to within
50 kb of transcription start or end sites of annotated genes based
on UCSC genome annotation (hg18). Bolton et al. designed tiling
arrays around the transcription start sites of 548 candidate
hormone-responsive genes and they identified 524 AR binding
regions using ChIP to chip analysis [34]. They found that only
67% of the 524 AR binding regions they identified were within
50 kb of the TSS of the androgen regulated genes [34].
Transcriptional factor (TF) binding sites can be localized to
regions other than the 59 proximal promoter regions, such as far
upstream sequences, introns, and 39 of the gene as exemplified by
genome-wide localization analysis (GWLA) of two transcription
factors (p53 and estrogen receptor) [35,36]. There is no consensus
about how far a TF can bind upstream of a TSS and still be
considered as its cis-regulatory TF of a given gene. Values ranging
from 1 kb to 100 kb of TSS have been used by others [35,36],
reflecting limited understanding of transcription factor binding.
The AR is known to be able to regulate genes from a far distance.
For example, Magee et al. showed that androgens directly regulate
FKBP5 via an interaction between the AR and a distal enhancer
located 65 kb downstream of the transcription start site in the fifth
intron of the FKBP5 gene [37]. Recently, Jariwala et al.
discovered 19 novel loci occupied by the AR in castration-
resistant C4-2B PCa cells by chromatin immunoprecipitation
(ChIP) display. They found that only four of the 19 AR-occupied
regions were within 10-kb 59-flanking regulatory sequences, while
three were up to 4-kb 39 of the nearest gene, eight were intragenic,
and four were in gene deserts [38]. Marioni et al. used RNA-seq to
map deep sequencing of mRNAs to the human genome; they
found that a significant portion of the mRNA sequences fall near
an annotated gene but not in the annotated region [39], which
suggests that annotations of many genes in the Ensembl or UCSC
require extension or revision. This imprecision may affect
mapping statistics of our AR binding data to the human genome.
In addition, they showed that a sizeable fraction (10.6%) mapped
to locations at least 100 kb from a known gene. This observation,
together with the published data from the ENCODE Project
Consortium [40], suggests that many transcriptionally active
regions (TARs) are currently unannotated [39]. Some of our AR
binding sites that we found to be localized in intergenic regions
may be localized to these TARs. Over expression of AR in PC3
cells will not necessary result in non-specific binding in a ChIP as
the specificity of binding in a ChIP experiment is determined by
antibody specificity and by the washing conditions. We have
optimized the ChIP conditions and identified an AR antibody that
yielded high specificity in the ChIP experiments (Figure S1).
We also compared our data to a global AR binding data set
from Massie et al., who identified 1,532 potential AR-binding sites
in AR responsive and proliferative LNCaP cells using the
NimbleGen promoter array that contains 1.5 kb promoter regions
of about 25K human genes [41]. As Massie et al. used only 1.5 kb
promoter, we compare 208 AR binding regions that localized
within 1.5 kb of the 59 of TSS sites, and we found that only 19
(9.1%) also mapped to the 1532 AR promoter regions in LNCaP
cells (Table S9). A one-sided Fisher’s exact test suggested that the
overlap is not significant (P=0.92). Wang et al. used ChIP to chip
to identify and map 90 AR binding sites on chromosomes 21 and
22 in a prostate cancer cell line LNCaP under the treatment of
100 nM of androgen 5a-dihydrotestosterone (DHT) for 1 hour
and 16 hours [12]. These 90 AR binding sites could be mapped to
27 genes; we identified only three of them (TMEM50B, BTG3
and MORC3) overlapping with our ChIP-seq data. The big
difference between our ChIP-seq data and other’s data is probably
due to several factors. First, different technologies (ChIP-seq v.s.
ChIP-chip) were used. Using NRSF as an example, Ji et al. showed
that 5,517 (78%) of 7,114 ChIP-chip peaks did not overlap with
the ChIP-seq peak [24]. They showed 933 (58.8%) of the 1,587
peaks common to ChIP-seq and ChIP-chip contain the NRSF
motif, and 20.9% of peaks identified by ChIP-seq but not found by
arrays contain the NRSF motif. However, only 68 (1.23%) of
5,517 ChIP chip specific peaks contain the NRSF motif [24].
Second, AR binding may require co-factors that are different in
Figure 4. The consensus sequences of the three novel AR
matrice identified, which can be mapped to 1,448, 1,012, 317
AR binding regions respectively. The consensus logos were
generated with the Web logo program (http://weblogo.berkeley.edu/)
using the mapped sequences from Table S5–S7.
doi:10.1371/journal.pone.0006589.g004
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et al. used LNCaP cells [12,41] while we used PC3 over-expressing
the wild type AR. Finally, both lists may contain come false
positives, which could reduce the chance of overlap. We used a
transient expression of AR in PC3 cells, which might cause over
representation of AR bindings.
We integrated the ChIP data with the gene expression data of
PC3-AR cells in response to androgens. We found that 859 AR
binding genes (1114 AR binding regions) (51.5%, 1,114/2,163,)
are differentially expressed at various concentrations of androgens
by at least two fold (Table S3 and Figure 1, lower panel). Other
AR binding genes may also be regulated by androgens by less than
two fold, of course. There is also a possibility that AR binding is a
pre-condition for androgen response, and other factors may be
needed for some promoters to turn AR binding into AR-response
(i.e changed expression levels).
Some of these AR binding regions are adjacent to genes that are
up regulated and others are adjacent to genes that are down
regulated by androgen (Table S1). This is consistent with the result
by Jariwala et al., who showed that, of 32 genes within 100 kb
from the 19 novel AR-occupied regions they identified by ChIP,
ten were stimulated by the AR but four were repressed in DHT-
treated C4-2B cells [38]. It is also possible that, for some
promoters, AR binding only poises the promoters for additional
binding of other factors, just like what Jia et al. showed that AR-
occupied regions in prostate cancer cells exceed number of DHT-
responsive genes [42]. We noticed that AR did bind to the
promoter regions of KLK3 (PSA) gene (Table S3) and confirmed
its enrichment in the AR-ChIP compared to IgG-IP (Figure S1),
but the expression level of KLK3 did not change even in the
presence of 1 nM or 10 nM of R1881, suggesting that other co-
factors are need to turn binding events into functional conse-
quences of changed gene expressions for some genes like KLK3.
We identified the top ranking co-occupancy transcription
factors for TEF1_Q6 (Transcriptional enhancer factor), GA-
TA_Q6 (GATA transcription factors), OCT_Q6 (octamer tran-
scription factors) and PU1_Q6 (PU.1 transcription factor). Wang
et al. identified GATA2 and Oct1 as cooperators of AR in
mediating the androgen response in LNCaP cells [12]. TEF1 and
PU1 are two putative novel AR cooperators that we identified for
PC3-AR cells. TEF1 is also named TEAD1 (TEA domain family
member 1, SV40 transcriptional enhancer factor). Recently,
Knight et al found that TEAD1 is novel prostate basal cell
markers that correlate with poor clinical outcome in prostate
cancer [43]. Knockdown TEAD1 expression using siRNA in
prostate cell lines led to decreased cell growth in PC3 and
disrupted acinar formation in a 3D culture system of RWPE1.
However, the interaction of TEAD1 and AR has not been studied
and future investigation is warranted. PU1 is also named
hematopoietic transcription factor, and it is ETS-domain tran-
scription factor that activates gene expression during myeloid and
B-lymphoid cell development [44]. Its role in prostate cancer or its
relationship with AR has not been studied.
We found that 190 sites (about 2.9%, 190 out of 6,629 AR
binding sites) contain the proliferative AR consensus matrix
M00481, M00447 and M00962 (from the Transfac database) with
a likelihood (LR) ratio of 500 compared to genomic background.
Our data is similar to Wang et al.’s findings that only 10% of the
binding regions that they identified have a canonical class I NR
(AGAACAnnnTGTTCT) binding motif when allowing up to two
positions to vary from the palindromic consensus with 3 nucleotide
spacing [12]. Massie et al. observed that 410 of 1,532 AR binding
regions (26.8%) contain the ARE sequence motif M00481
(consensus: GGTACANNRTGTTCT) [41]. We have identified
a lower percentage of AR binding regions contain the AR
consensus site, probably due to the stringent criterion we used, or
suggesting that the AR binding consensus for the prohibitive
response in PC3-AR cells is different from that of the proliferative
cells such as LNCaP cells. This maybe not surprising as the
consensus sequences for the AR in the Transfac database are
derived either from in vitro binding data or from a limited numbers
of human promoters: the M00481 (consensus: GGTACANN-
RTGTTCT) was built from 29 binding sites selected from random
oligonucleotides [25]; M00447 (consensus sequence AGWA-
CATNWTGTTCT) was derived from AR binding sites in mouse
crisp3 (cysteine-rich secretory protein 3)[26]; M00962 (consensus
sequence WGAGCANRN) is derived from 30 compiled AR
regulated genes but only four of them are human genes
[p21WAF1, PIGR (polymeric immunoglobulin receptor), AR
and KLK3] (from the Transfac database). Non-consensus ARE
sequences such as 59-GTAAAGTACTCCAAGAA-39 were previ-
ously identified for the androgen-regulated gene probasin [45,46].
We therefore proceed to see whether we can identify novel AR
consensus that explain the AR bindings in PC3-AR cells. We
identified three novel AR matrices (Figure 4) that can be mapped
to 1,448, 1,012, 317 AR binding regions respectively (Table S6–
S7), which is much higher than the number of mapped AR
binding regions using the three known canonical AR motifs from
the Transfac database as we showed above. The consensus
sequences of the new motif Gib1 and Gib2 are very similar, as
both share a common core sequence motif CGAGCTCTTC.
Motif Gib1 extends 39 end two nucleotides (CG) and motif Gib2
extends 59 end two nucleotides (TN) (N, any nucleotide) (Figure 4).
The union of the AR binding regions containing one of these two
motifs gives 1,808 AR binding regions, which explains 27.3%
(1,808/6,629) of the AR binding events in PC3-AR cells. Our
result suggests that the AR binding motif in PC3-AR cells might be
very different from the canonical AR motif that was defined using
androgen responsive prostate cells. Future mutagenesis and
functional analysis is necessary to truly define these new AR
motifs as functional AR binding motifs.
Materials and Methods
Chromatin IP
PC3 cells (catalogue # CRL-1435) were obtained from ATCC
(http://www.atcc.org/). We transfected a full-length wild-type AR
into PC3 prostate cancer cells that do not express the AR. The AR
construct is a generous gift from Dr. Donald J. Tindall at the
Mayo Clinic in Rochester. In this construct (pCMVhAR), the
wide-type AR is placed under the CMV promoter. Lipofectimi-
neTM 2000 reagent (Promega Inc.) was used for transfection
according to the manufacturer’s protocol. For chromatin immu-
noprecipitation (ChIP), two anti-AR antibodies from BD Pharma-
gen were tested for their performance (data not shown). The
specificities of the chromatin IP of the two AR antibodies were
tested by PCR amplification of the promoter of the prostate
specific antigen (PSA) gene, a gene that is directly regulated by the
AR [47]. The antibody (BD Pharmagen Cat No. 554224) that has
higher specificity was used (data not shown) in the final AR ChIP.
For ChIP, 48 hours after transfection, the protein was cross-linked
to DNA by adding formaldehyde according to the protocol by
Upstate’s chromatin immonoprecipitation kit. A no-antibody
control chromatin IP was also performed. The DNAs isolated
with anti-AR chromatin IP show a specific band corresponding to
the PSA promoter, and the DNAs isolated with ‘no-antibody’
chromatin IP do not (Figure S1).
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The chromatin IP DNA was digested with proteinase K and
then purified by Qiagen Qiaquick PCR purification kit. ChIP
DNA end repairing, adaptor ligation, and amplification were
performed as described earlier [21]. Fragments of about 100 bp
(without linkers) were isolated from agarose gel and used for
sequencing using the Solexa/Illumina 1 G genetic analyzer.
ChIP-seq data analysis
Solexa Pipeline Analysis was performed as described [21].
Sequence reads that map to multiple sites in the human genome
were removed. The output of the Solexa Analysis Pipeline was
converted to browser extensible data (BED) files for viewing the
data in the UCSC genome browser. To identify AR binding
regions, CisGenome was used for data analysis using two-sample
mode with the AR ChIP-seq as positive and the IGG control
ChIP-seq data as negative input. To calculate the distance to a
TSS start site, annotations from the UCSC genome browser were
used. We also took into the consideration of the direction of the
strand when calculating the distance to TSS. As the AR binding
regions is always recorded on the positive strands, for genes
mapped to the positive strand, the distance is the end position of
the AR binding region minus the TSS start position; for genes
mapped to the negative strand, the distance is the TSS start
position minus the AR binding region start position.
Motif Scanning and identification
To scan for matched of single TF position-weight matrix, we
used Cisgenome program using the ‘‘single matrix R FASTA’’
function. The matching criteria was set at likelihood ratio
(LR).=500, and the order of background Markov Chain was
set to three. We used the Gibbs Motif Sampler of the CisGenome
program to identify novel AR binding motifs in the AR binding
regions with a likelihood (LR) ratio of 500 compared to IGG
ChIP-Seq background. For a systematic search for all potential
transcription binding sites, we used the stand-alone motif scanner
software (http://homes.esat.kuleuven.be/,thijs/download.html).
Human upstream sequences from EPD (The Eukaryotic Promoter
Database) (epd_homo_sapiens_499_chromgenes_non_split_3.bg)
were downloaded from the motif scanner web site and used as
the background model. The human subset of the Transfac
professional 7.0 PWM matrices was used. Matched matrices with
likelihood (LR) ratios of 500 or higher were tabulated and
frequency calculated.
Expression profiling and data analysis
PC3 cells were starved for 48 hours in androgen-deprived
medium containing 10% dextran-filtered, charcoal-stripped fetal
calf serum, and then transfected with pCMVhAR construct or
vector alone (MOCK) using lipofectimineTM 2000 reagent
(Promega Inc.) according to the manufacturer’s protocol. Twen-
ty-four hours after transfection, the culture media were replaced
with culture media containing ETOH (solvent for R1881), or
1 nM R1881 or 10 nM R1881. Cells were harvested 48 hours
transfection (i.e. 24 hours after change of media) and RNAs
isolated according to the method we described previously [48]. We
have performed two biological replicates for the MOCK
condition, ETOH condition and the 1 nM condition. We
compared the biological replicates and saw that they are highly
consistent with correlation scores of 0.995, 0.993 and 0.995
respectively for all probes (Figure S2 and S3). For the 10 nM
condition, we only completed one replicate due to lack of arrays
from the same batch. As the biological replicates are highly
reproducible, the data should be consistent and comparable to the
other conditions.
Affymetrix U133Plus2 chips were used and standard array
hybridization protocol as suggested by the manufacturer as used.
Array data were normalized by the GCRMA method [49]. To
determine present (absent) probesets, we applied a Gaussian
mixture modeling method [50] to the normalized data set as
follows: 1) Two Gaussian probability density functions (PDFs), one
for ‘absent’ probesets and the other for ‘present’ probesets, were
fitted to the distribution of the observed probeset intensities; and 2)
Among 54,675 probesets, 26,056 probesets whose maximum
intensities in all arrays were higher than the threshold where two
fitted Gaussian PDFs meet were identified as present. The average
normalized intensities were used for biological replicates (MOCK,
ETOH and 1 nM conditions). For each experimental condition
(ETOH, 1 nM and 10 nM conditions), present genes with
absolute fold change higher than two were chosen as differentially
expressed genes (DEGs)
Statistical Analysis
We applied one-sided Fisher’s exact test for testing the
significant of enrichment. In additional, we also calculated the P
values from Gaussian fitting using 10000 randomizations by
randomly sampling. We identified 152 genes that overlap between
the 2328 PC3 AR DEGs and 757 LNCAP AR DEGs. The union
of these two gene lists gave a list of 2933 genes. The following
procedure was performed to compute the probability that the
number of overlapping genes in the two lists exceed the observed
152 genes by chance: 1) we randomly sampled 757 genes
independently from 2933 AR-regulated genes, 2) the number of
overlapping genes between the two randomly sampled gene sets
was counted, 3) the above steps were repeated 10000 times, 4) an
empirical probability density function was fitted to the 10000
numbers of overlapping genes from random experiments, 4) a p-
value was computed as 1- normcdf (152,m,s) where m and s are
the mean and standard deviation estimated from the normal
distribution fitting.
Supporting Information
Table S1 4166 differentially expressed genes in PC3-AR cells
compared to Mock-transfected PC3 cells and compared to
themselves at 1 nM and 10 nM androgen treatment conditions.
Found at: doi:10.1371/journal.pone.0006589.s001 (0.85 MB
XLS)
Table S2 Gene Ontology Enrichment analysis of differentially
expressed genes.
Found at: doi:10.1371/journal.pone.0006589.s002 (0.05 MB
XLS)
Table S3 AR binding regions identified in PC3-AR cells.
Found at: doi:10.1371/journal.pone.0006589.s003 (3.60 MB
XLS)
Table S4 Known AR consensus matrice from the Transfac
Database mapped to AR binding regions identified.
Found at: doi:10.1371/journal.pone.0006589.s004 (0.01 MB
TXT)
Table S5 Mapping of novel AR motif Gib1 to the AR binding
regions of PC3-AR cells
Found at: doi:10.1371/journal.pone.0006589.s005 (0.08 MB
XLS)
Table S6 Mapping of novel AR motif Gib2 to the AR binding
regions of PC3-AR cells.
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XLS)
Table S7 Mapping of novel AR motif Gib3 to the AR binding
regions of PC3-AR cells.
Found at: doi:10.1371/journal.pone.0006589.s007 (0.02 MB
XLS)
Table S8 Ranking of known TF matches to the AR binding
regions of PC3-AR cells identified by MotifScanner.
Found at: doi:10.1371/journal.pone.0006589.s008 (0.06 MB
DOC)
Table S9 Comparison of AR binding regions of PC3-AR cells
and LNCaP cells within 1.5 kb of TSS sites.
Found at: doi:10.1371/journal.pone.0006589.s009 (0.05 MB
XLS)
Figure S1 ChIP with the AR antibody generated a band that is
the same size as the positive (input) control. ChIP without the
primary AR antibody (without Ab) but with the 2nd antibody IgG
alone generate no-specific PCR product, suggesting the AR ChIP
is specific. The negative control (no template) showed negative.
The bottom bands across the lanes are primer dimmer.
Found at: doi:10.1371/journal.pone.0006589.s010 (0.15 MB TIF)
Figure S2 Quality control scatter plot of replicate array
hybridization showing the replicates are of good qualities.
Found at: doi:10.1371/journal.pone.0006589.s011 (1.68 MB TIF)
Figure S3 Scatter plot comparing Mock (empty vector) vs. AR
transfected PC3 cells in different androgen conditions. When
compared with the scatter plot of the replicates, differential
expression of genes is evident.
Found at: doi:10.1371/journal.pone.0006589.s012 (1.72 MB TIF)
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